TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Crossover Study of the Acute Effects of Olanzapine in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy Volunteer~* Body Mass Index of 18.5-25 kilograms per square meter~* Must be able to swallow tablets~* Able to give informed consent~Exclusion Criteria:~* Any DSM-IV TR Axis I psychiatric disorder (except nicotine dependence)~* Presence of any medical disorder that may confound the assessment of relevant biologic measures, including: significant organ system dysfunction, metabolic diseases, type 1 diabetes mellitus, type 2 diabetes mellitus, pregnancy, endocrine disease, coagulopathy, clinically significant anemia, or acute infection~* Subjects who have taken any antipsychotic medication within the last 6 months~* Personal or family history of seizures and/or cardiac arrhythmias

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 30 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo
- Olanzapine (Type: EXPERIMENTAL): Olanzapine 10mg po daily x 3 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Gemcitabine/Cisplatin/S-1(GCS) Combination Therapy for Patients With Advanced Biliary Tract Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 1. Patients with cytologically or histologically proved biliary tract cancer 2. age \>=20 years 3. PS 0-2 4. No prior history of chemotherapy or radiotherapy. Patients who have undergone adjuvant chemotherapy are eligible if at least 6 months have passed since the last administration.~  5. Adequate bone marrow function (neutrophil count \>=1,500/mm3, and platelet count \>=100,000/mm3), liver function (total bilirubin \>=3 mg/dL and AST/ALT \>=150 IU/L), and renal function (creatinine clearance \>=60 mL/min) 6.No other serious comorbid disease 7.Adequate oral intake 8.Provided written informed consent~Exclusion Criteria:~* 1. Patients with interstitial pneumonia or pulmonary fibrosis 2. Patients with uncontrollable diabetes mellitus, liver disease, angina pectoris or a new onset of myocardial infarction within 3 months 3. Patients with severe active infection 4. Patients who are pregnant or lactating, or have an intention to get pregnant 5. Patients with a history of severe drug allergy 6. Patients with other serious comorbid disease 7. Patients with mental disease 8. Patients who are judged inappropriate for the entry into the study by the principle doctor 9. Patients with watery diarrhea

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- S-1, Gemcitabine, Cisplatin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a histologic or cytologic diagnosis of intrahepatic cholangiocarcinoma with stage IV;~* Have progressed after systematic chemotherapy/target therapy, or cannot tolerated with first-line treatment;~* The previous treatment and the present trial registration must be at least 2 weeks apart, and they must have recovered from any toxicity of a previous treatment;~* Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1;~* Eastern Cooperative Oncology Group performance score (ECOG): 0-2;~* Life expectancy of at least 12 weeks;~* Subjects who understand and voluntarily signed a written informed consent form.~Exclusion Criteria:~* Previous locoregional therapy within 4 weeks prior to enrollment.~* Diagnosed with hepatocellular carcinoma, mixed cell carcinoma and fibrolamellar hepatocellular carcinoma.~* History of other malignancy within 5 years except for non-melanoma skin cancer, cervix in situ carcinoma.~* Prepared for liver transplantation.~* Patients with contraindications (active bleeding, ulcers, intestinal perforation, intestinal obstruction, within 30 days after major surgery, uncontrolled high blood pressure medication, III-IV level cardiac insufficiency, severe liver and kidney dysfunction).~* A previous history of Interstitial pulmonary disease, drug-induced interstitial disease, radiation pneumonitis requiring hormonal therapy or active interstitial lung disease with any clinical evidence.~* Use of CYP3A4 inhibitor within 7 days or CYP3A4 inducer within 12 days prior to enrollment.~* Patients with central nervous system metastases or brain metastasis~* Previous definite diagnosis of neuropsychiatric disturbances, including epilepsy or dementia.~* Pregnant or lactating women.~* Patients with bone metastasis received palliative radiation within 4 weeks prior to enrollment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Apatinib (Type: EXPERIMENTAL): A molecular targeted anti-tumor drugs. Small molecule vascular endothelial growth factor receptor 2 inhibitor.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sensoril(Ashwaganhda)for Bipolar Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* DSMIV-TR diagnosis of Bipolar Disorder~* Ages 18 to 65~* Men or Women~* 8th grade education or greater~* Able to provide competent written informed consent~* Current main mood stabilizer and mood status (YMRS and MADRS scores less than or equal to 10) are stable for greater than or equal to 4 weeks by history.~Exclusion Criteria:~* Medically unstable conditions~* Known allergy to Sensoril® (or Ashwagandha)~* Current cognitive decline is attributable to a diagnosis of dementia or other neurological disorder~* Pregnant or lactating women~* Mini-mental score (MMSE) less than or equal to 23~* Currently receiving donepezil, rivastigamine, or galatamine, or memantine or any marketed agent for slowing memory loss in dementia~* Abnormal clinical thyroid status~* Currently (or within past 2 weeks) receiving St. John's Wort, Gingko or Omega-3

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1- Sensoril (Ashwagandha) (Type: EXPERIMENTAL): Sensoril (Ashwagandha) will be administered using random assignment at a dose of 250 mg/day, increasing to a dose of 500 mg/day by the second week.
- 2 - Placebo (Type: PLACEBO_COMPARATOR): Placebo will be administered using random assignment at a dose of 250 mg/day, increasing to a dose of 500 mg/day by the second week.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Gemcitabine With Antiangiogenic Peptide Vaccine Therapy in Patients With Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~DISEASE CHARACTERISTICS~1. locally advanced or metastatic pancreatic cancer precluding curative surgical resection and recurrent pancreatic cancer~2. measurable disease by CT scan~PATIENT CHARACTERISTICS~1. ECOG performance status 0-2~2. Life expectancy \> 3 months~3. Laboratory values as follows~   * 2000/mm3 \< WBC \< 15000/mm3~  * Platelet count \> 75000/mm3~  * Bilirubin \< 3.0 mg/dl~  * Aspartate transaminase \< 150 IU/L~  * Alanine transaminase \< 150 IU/L~  * Creatinine \< 3.0 mg/dl~4. HLA-A\*2402~5. Able and willing to give valid written informed consent~Exclusion Criteria:~1. Pregnancy(woman of childbearing potential:Refusal or inability to use effective means of contraception)~2. Breastfeeding~3. Active or uncontrolled infection~4. Concurrent treatment with steroids or immunosuppressing agent~5. Prior chemotherapy of gemcitabine~6. Prior chemotherapy,radiation therapy, or immunotherapy within 4 weeks~7. Serious or nonhealing wound, ulcer, or bone fracture~8. Active or uncontrolled other malignancy~9. Ileus~10. Interstitial pneumonia~11. Decision of unsuitableness by principal investigator or physician-in-charge

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Phase I study (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Melatonin Supplements for Improving Sleep in Individuals With Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with uncomplicated hypertension~* Currently being treated with Atenolol (a beta-blocker)~Exclusion Criteria:~* History of medical illness other than essential hypertension~* Personal or family history of psychiatric illness~* Current use of any medication other than anti-hypertensive drugs~* Any recent travel across time zones~* History of working various shifts on an irregular basis

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Melatonin (2,5 mg, by mouth, 1 per day, for 3-4 weeks)
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Low-dose Nilotinib and Imatinib Combination in Chronic Myeloid Leukemia Patients, With Failure, Suboptimal Response or Treatment Intolerance

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* CML patients with failure or suboptimal response to imatinib therapy according to criteria established by the European Leukemia Net (ELN)~* Patients with grade II or higher adverse events.~* CML patients not suitable for stem cell transplantation.~Exclusion Criteria:~* Patients in blast crisis.~* Pregnant women~* Patients without a contraception method.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Imatinib and nilotinib combination (Type: EXPERIMENTAL): All patients will receive treatment as follows: imatinib 100 mg tablets, 200 mg daily for 6 months; and nilotinib 150 mg capsule, 300 mg daily for 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Analgesic Effect of Combined Nerve Block and Systemic High Dose Glucocorticoid After Total Knee Arthroplasty.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age\> 50 years~* Patients set to cemented Total knee arthroplasty in spinal block~* ASA 1-3~Exclusion Criteria:~* Patients who can not cooperate with the investigation~* Patients who have given written informed consent to participate in the study after having understood the contents of the protocol and limitations fully~* Patients who do not understand or speak Danish~* Patients receiving immunosuppressive therapy~* Patients receiving glucocorticoid daily~* Patients with a treatment-dependent diabetes mellitus~* Patients with known neuropathy in the lower limbs~* Allergy to those used in the study drugs~* Alcohol and / or drug abuse - the investigator's opinion~* Patients who can not tolerate NSAIDs~* Fixed several times daily consumption of strong opioids (morphine, ketogan, Oxynorm, methadone, fentanyl)

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Combined nerve block (Type: EXPERIMENTAL): Ropivacaine and Adrenalin, systemic Ketorolac and high dose Dexamethasone
- Local infiltrationanalgesia (Type: ACTIVE_COMPARATOR): Ropivacaine, Adrenalin and Ketorolac combined with systemic high dose dexamethasone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of IBI306 in HeFH Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~• Subjects must meet all of the following inclusion criteria in order to be included in the study:~* Provide a signed and dated informed consent form~* Men or women 18 to 70 years of age at screening~* Weight ≥ 40 kg during screening~* Confirmed diagnosis of heterozygous familial hypercholesterolemia~* Maintain a low-fat diet and stabilize the current lipid-lowering therapy~Exclusion Criteria:~• Subjects who do not meet any of the following exclusion criteria cannot be included in the study:~* Patients diagnosed as homozygous familial hypercholesterolemia~* Dialysis or plasmapheresis performed within 4 months prior to screening~* History of liver transplant~* Subjects adjusted for treatment of statins, ezetimibe, niacin, omega-fatty acids within 4 weeks prior to screening~* New York Heart Association (NYHA) grade III or IV heart failure, or recent detection of left ventricular ejection fraction ≤ 30%~* Have serious cardiovascular, cerebrovascular, liver and kidney related diseases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- IBI306 (Type: EXPERIMENTAL): Participants received IBI306 150 mg subcutaneously Q2W or 450mg Q4W for 12 weeks.
- placebo (Type: EXPERIMENTAL): Participants received Placebo 150 mg subcutaneously Q2W or 450mg Q4W for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: BI 655066 (Risankizumab) Compared to Placebo in Japanese Patients With Moderate to Severe Chronic Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have a diagnosis of chronic plaque psoriasis (with or without psoriatic arthritis) for at least 6 months before the first administration of study drug. Duration of diagnosis may be reported by the patient.~* Have stable moderate to severe chronic plaque psoriasis with or without psoriatic arthritis at both Screening and Baseline (Randomisation):~  1. Have an involved body surface area (BSA) ≥10% and~ 2. Have a Psoriasis Area and Severity Index (PASI) score ≥12 and~ 3. Have a Static Physician Global Assessment (sPGA) score of ≥3.~Exclusion Criteria:~* Patients with~  1. non-plaque forms of psoriasis (including guttate, erythrodermic, or pustular)~ 2. current drug-induced psoriasis (including an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)~ 3. active ongoing inflammatory diseases other than psoriasis and psoriatic arthritis that might confound trial evaluations according to investigator's judgment~* Previous exposure to BI 655066

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Part A) (Type: PLACEBO_COMPARATOR): Participants randomized to receive double-blind (DB) placebo for risankizumab by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
- Risankizumab 75 mg (Part A) (Type: EXPERIMENTAL): Participants randomized to receive double-blind (DB) risankizumab 75 mg by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
- Risankizumab 150 mg (Part A) (Type: EXPERIMENTAL): Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has moderate to severe plaque psoriasis for 6 months or longer with at least 10% Body Surface Area (BSA) affected~* Subject must be a candidate for phototherapy and/or systemic therapy~Exclusion Criteria:~* Subject has non-plaque psoriasis or drug-induced psoriasis~* Subject is on systemic psoriasis therapy within 56 days or 5 half-lives, whichever is longer, prior to first dose of study drug~* Subject has a positive TB skin test within 3 months of screening or at screening~* Subject has an abnormal chest x-ray

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): lowest dose
- Group 2 (Type: EXPERIMENTAL): low dose
- Group 3 (Type: EXPERIMENTAL): high dose
- Group 4 (Type: EXPERIMENTAL): highest dose
- Group 5 (Type: EXPERIMENTAL): medium dose
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Smoking Cessation in Subjects With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD).

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects will be current cigarette smokers who have smoked an average of at least 10 cigarettes per day during the past year and during the month prior to the screening visit.~* mild to moderate COPD confirmed by spirometry~* Subjects must have a clinical diagnosis of COPD.~Exclusion Criteria:~* Subjects who have made a serious attempt to quit smoking in the past 3 months.~* Subjects who have been previously randomized in a study that has included varenicline.

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): None
- varenicline (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Multimodal Analysis and Electroretinogram in VKH From Acute Onset - Part I

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* clinical diagnosis of Vogt-Koyanagi-Harada disease~* acute onset with no previous treatment~Exclusion Criteria:~* non-acute VKHD~* media opacities

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Corticosteroid monotherapy (Type: OTHER): All patients in the acute phase will be treated with corticosteroid monotherapy, unless presents a contraindication or persistence/ recurrence of inflammation with regressive corticosteroid monotherapy.This is the unique arm of the present study.~Treatment protocol includes a three-day course of intravenous methylprednisolone (1000 mg per day) followed by a high dose of oral prednisone (1.0 mg/kg/day) with a slow tapering with dose equal or less than 0.1mg/kg/day after 10 months. The prednisone dose is scheduled to be reduced in a 0.1 mg/kg-step ladder until it reaches 0.3 mg/kg (i.e. for an individual with 60 kg, dose would be 20 mg): from 1 to 0.8 mg/kg every two to three weeks; at 0.7 mg/kg for 4 weeks; at 0.6 mg/kg for two to three weeks; from 0.5 mg/kg every 4 weeks; from 0.3 to 0.15 mg/kg every 6 weeks; and 0.1 mg/kg, 0.075 mg/kg and 0.05 mg/kg for 8 weeks each.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ketofol vs Propofol for Emergency Department Procedural Sedation and Analgesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 14 years or greater~* deemed to require emergency department procedural sedation by the attending physician~Exclusion Criteria:~* unable to give informed consent~* hemodynamic instability~* pregnancy~* known allergy to either study medication

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Propofol alone (Type: ACTIVE_COMPARATOR): Patients receiving propofol alone.
- Ketofol (Type: ACTIVE_COMPARATOR): 0.375 mg/kg each of ketamine and propofol (mixed in the same syringe) as an initial bolus and 0.188 mg/kg each of ketamine and propofol as necessary until reaching deep sedation (Ramsay score = 5 or greater).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete